GSK, CureVac say to develop vaccine targeting Covid variants
“The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval”
Representational Image. Photo: Reuters
British pharmaceutical group GlaxoSmithKline and German biotech firm CureVac on Wednesday announced plans to jointly develop a coronavirus vaccine with the potential to treat multi-variants of Covid-19.
"The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval," a joint statement said.
Keep updated, follow The Business Standard's Google news channel
